• 1
    Seifried HE. Oxidative stress and antioxidants: a link to disease and prevention? J Nutr Biochem 2007; 18: 16871.
  • 2
    Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J 2007; 401: 111.
  • 3
    Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans 2007; 35: 114750.
  • 4
    Lee IM. Antioxidant vitamins in the prevention of cancer. Proc Assoc Am Physicians 1999; 111: 105.
  • 5
    Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the ‘antioxidant hypothesis’. Public Health Nutr 2004; 7: 40722.
  • 6
    Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 2004; 44: 27595.
  • 7
    Gonzalez CA. Nutrition and cancer: the current epidemiological evidence. Br J Nutr 2006; 96: S425.
  • 8
    Huang HY, Caballero B, Chang S, et al. Multivitamin/mineral supplements and prevention of chronic disease. Evid Rep Technol Assess 2006; 139: 1117.
  • 9
    Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med 2004; 19: 3809.
  • 10
    Coulter ID, Hardy ML, Morton SC, et al. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. J Gen Intern Med 2006; 21: 73544.
  • 11
    Greenwald P, Anderson D, Nelson SA, Taylor PR. Clinical trials of vitamin and mineral supplements for cancer prevention. Am J Clin Nutr 2007; 85: 314S7S.
  • 12
    Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence. Mortality and Prevalence Worldwide. IARC Cancer Base no. 5, Version 2.0. Lyon (France): IARC Press, 2004.
  • 13
    Giacosa A, Filiberti R, Hill MJ, Faivre J. Vitamins and cancer chemoprevention. Eur J Cancer Prev 1997; 1: S4754.
  • 14
    Garcea G, Dennison AR, Steward WP, Berry DP. Chemoprevention of gastrointestinal malignancies. ANZ J Surg 2003; 73: 6806.
  • 15
    Sharma N, Trope B, Lipman TO. Vitamin supplementation: what the gastroenterologist needs to know. J Clin Gastroenterol 2004; 38: 84454.
  • 16
    Grau MV, Rees JR, Baron JA. Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 2006; 98: 2817.
  • 17
    Stoner GD, Wang LS, Chen T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 2007; 224: 33749.
  • 18
    Mehta S, Johnson IT, Rhodes M. Systematic review: the chemoprevention of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2005; 22: 75968.
  • 19
    Leung WK, Sung JJ. Chemoprevention of gastric cancer. Eur J Gastroenterol Hepatol 2006; 18: 86771.
  • 20
    Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007; 76: 5167.
  • 21
    Doucas H, Garcea G, Neal CP, Manson MM, Berry DP. Chemoprevention of pancreatic cancer: a review of the molecular pathways involved, and evidence for the potential for chemoprevention. Pancreatology 2006; 6: 42939.
  • 22
    Yates MS, Kensler TW. Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 2007; 28: 133142.
  • 23
    Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004183. DOI: DOI: 10.1002/14651858.CD004183.pub2.
  • 24
    Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364: 121928.
  • 25
    HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd., 2006.
  • 26
    Bjelakovic G, Nikolova D, Simonetti R. Antioxidants for preventing gastrointestinal cancers (protocol for a Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software, 2003.
  • 27
    International Committee on Harmonization. Code of Federal Regulations & Guidelines. Vol. 1, Philadelphia, US: Barnett International/PAREXEL, 1997.
  • 28
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 40812.
  • 29
    Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet 1998; 352: 60913.
  • 30
    Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 9829.
  • 31
    RevMan Analyses [Computer program]. Version 1.0 for Windows. In: Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
  • 32
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 33
    DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 34150.
  • 34
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 35
    Sharp SJ. Meta-analysis regression. Stata Technical Bulletin 1998; 42: 1622.
  • 36
    McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials. A systematic review. JAMA 2003; 289: 254553.
  • 37
    Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
  • 38
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088101.
  • 39
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 40
    Munoz N, Wahrendorf J, Bang LJ, et al. No effect of riboflavine, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China. Lancet 1985; 2: 1114.
  • 41
    Yu SY, Zhu YJ, Li WG, et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 1991; 29: 28994.
  • 42
    Blot WJ, Li JY, Taylor PR, et al. Nutrition Intervention Trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 148392.
  • 43
    Li JY, Taylor PR, Li B, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993; 85: 14928.
  • 44
    Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11: 6309.
  • 45
    Cook NR, Le IM, Manson JE, Buring JE, Hennekens CH. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians’ Health Study (United States). Cancer Causes Control 2000; 11: 61726.
  • 46
    Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Re 1997; 56: 11724.
  • 47
    Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 18818.
  • 48
    Li W, Zhu Y, Yan X, et al. The prevention of primary liver cancer by selenium in high risk populations. Zhonghua Yu Fang Yi Xue Za Zhi 2000; 34: 3368.
  • 49
    Anonymous 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 2333.
  • 50
    Virtamo J, Pietinen P, Huttunen JK, et al. ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003; 290: 47685.
  • 51
    Zhu S, Mason J, Shi Y, et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J 2003; 116: 159.
  • 52
    Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 2004; 96: 174350.
  • 53
    Li H, Li HQ, Wang Y, et al. An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum. Chin Med J 2004; 117: 115560.
  • 54
    Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164: 233542.
  • 55
    Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 133847.
  • 56
    Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005; 294: 5665.
  • 57
    You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 97483.
  • 58
    Plummer M, Vivas J, Lopez G, et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 2007; 99: 13746.
  • 59
    Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant Cardiovascular Study. Arch Intern Med 2007; 167: 16108.
  • 60
    Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64: 52742.
  • 61
    Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147: 21723.
  • 62
    Costello AJ. A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: rationale, recruitment, and design issues. Urology 2001; 57: 1824.
  • 63
    Klein EA, Thompson IM, Lippman SM, et al. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003; 21: 5965.
  • 64
    Marshall JR, Sakr W, Wood D, et al. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 147984.
  • 65
    Gluud C, Nikolova D. Quality assessment of reports on clinical trials in the Journal of Hepatology. J Hepatol 1998; 29: 3217.
  • 66
    Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003; 7: 176.
  • 67
    Gluud LL. Bias in clinical intervention research. Am J Epidemiol 2006; 163: 493501.
  • 68
    Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatol 2006; 44: 60715.
  • 69
    Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006; 174: 63541.
  • 70
    Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 84257.
  • 71
    Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 201723.
  • 72
    Caraballoso M, Sacristan M, Serra C, Bonfill X. Drugs for preventing lung cancer in healthy people. The Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002141. DOI: 10.1002/14651858.CD002141.
  • 73
    Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs DR Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004; 80: 1194200.
  • 74
    Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007; 99: 75464.
  • 75
    Slatore CG, Littman AJ, Au DH, Satia JA, White E. Supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med 2008; 177: 52430.
  • 76
    Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 174757.
  • 77
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
  • 78
    Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 2007; 6: 28093.
  • 79
    Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 2001; 20(Suppl): 464S72S.
  • 80
    Haenen GR, Bast A. The use of vitamin supplements in self-medication. Therapie 2002; 57: 11922.
  • 81
    Herbert V. The value of antioxidant supplements vs their natural counterparts. J Am Diet Assoc 1997; 97: 3756.
  • 82
    Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003; 63: 42958.
  • 83
    Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature 1998; 392: 559.
  • 84
    Paolini M, Pozzetti L, Pedulli GF, Marchesi E, Cantelli-Forti G. The nature of prooxidant activity of vitamin C. Life Sci 1999; 64: 2738.
  • 85
    Murata M, Kawanishi S. Oxidative DNA damage by vitamin A and its derivative via superoxide generation. J Biol Chem 2000; 275: 20038.
  • 86
    Lee BM, Park KK. Beneficial and adverse effects of chemopreventive agents. Mutat Res 2003; 24: 26578.
  • 87
    Duarte TL, Lunec J. Review: when is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C. Free Radic Res 2005; 39: 67186.
  • 88
    Camire ME, Kantor MA. Dietary supplements: nutritional and legal considerations. Food Technol 1999; 53: 8795.
  • 89
    Panel on Micronutrients, Subcommittees on Upper Reference Levels of Nutrients and of Interpretation and Use of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington DC: National Academy Press, 2000: 1800.
  • 90
    Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of DRIs, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Institute of Medicine. Dietary reference intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000: 1529.
  • 91
    Herbert V. The antioxidant supplement myth. Am J Clin Nutr 1994; 60: 1578.
  • 92
    Schwartz JL. The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. J Nutr 1996; 126: 1221S7S.
  • 93
    Mulholland CA, Benford DJ. What is known about the safety of multivitamin-multimineral supplements for the generally healthy population? Theoretical basis for harm. Am J Clin Nutr 2007; 85: 318S22S.
  • 94
    Woo JJ. Adverse event monitoring and multivitamin-multimineral dietary supplements. Am J Clin Nutr 2007; 85: 323S4S.
  • 95
    Webb GP. Nutritional supplements and conventional medicine; what should the physician know? Proc Nutr Soc 2007; 66: 4718.
  • 96
    Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat Methods Med Res 2005; 14: 51524.
  • 97
    Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 245765.
  • 98
    Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004; 171: 73540.
  • 99
    Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 2005; 330: 753.
  • 100
    Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007; 297: 46870.
  • 101
    Nouraie M, Pietinen P, Kamangar F, et al. Fruits, vegetables, and antioxidants and risk of gastric cancer among male smokers. Cancer Epidemiol Biomarkers Prev 2005; 14: 208792.
  • 102
    Neuhouser ML, Patterson RE, Thornquist MD, Omenn GS, King IB, Goodman GE. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol Biomarkers Prev 2003; 12: 3508.
  • 103
    Lanza E, Yu B, Murphy G, Albert PS, et al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 2007; 16: 174552.
  • 104
    Larsson SC, Håkansson N, Näslund I, Bergkvist L, Wolk A. Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 3015.
  • 105
    Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer 2007; 121: 275360.
  • 106
    Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 2007; 99: 147183.
  • 107
    Kubo A, Corley DA. Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Am J Gastroenterol 2007; 102: 232330.
    Direct Link:
  • 108
    Takachi R, Inoue M, Ishihara J, et al. Fruit and vegetable intake and risk of total cancer and cardiovascular disease: Japan Public Health Center-based Prospective Study. Am J Epidemiol 2008; 167: 5970.
  • 109
    Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 3746.
  • 110
    Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment Pharmacol Ther 2006; 24: 28191.
  • 111
    Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 139: 5670.
  • 112
    U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease: recommendations and rationale. Ann Intern Med 2003; 139: 515.
  • 113
    McKevith B, Kelly C, Stanner S, Hughes J, Buttriss J. The Food Standards Agency’s antioxidants in food programme-a summary. J Hum Nutr Diet 2003; 16: 25763.